Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Males or females between the ages of 18 and 65 suffering from seasonal allergic rhinitis provoked by ragweed pollen.~* Having a 2-year history of seasonal allergic rhinitis with positive skin prick test to ragweed allergen at screening with a wheal diameter at least 3 mm larger than that produced by the negative control.~* Subjects with antecedents of allergic seasonal allergic rhinitis symptom aggravation when exposed to pollen and air pollutants (i.e., cleaning products, diesel, paints).~* Subjects having a total nasal symptom score ≥3 in Period 1 (Visit 2).~Exclusion criteria:~* History of anaphylaxis to ragweed pollen.~* History of asthma. Mild asthmatics treated only with pro re nata short-acting beta2-agonists, 2 doses or less per week can be enrolled.~* History of chronic sinusitis.~* History of systemic disease affecting the immune system.~* Evidence of any active or suspected bacterial, viral, fungal or parasitic infections within 30 days prior to allergen challenge.~* Any history of Grade 4 anaphylaxis due to any cause as defined by the Common Terminology Criteria for Adverse Event grading criteria (Life threatening consequences: urgent intervention indicated).~* Presence or history of drug hypersensitivity to fexofenadine.~* Subjects receiving build-up injections of pollen allergen immunotherapy (those on stable maintenance dosing can be included).~* Subjects taking any forbidden treatments/nutriments.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fexofenadine (Type: EXPERIMENTAL): Fexofenadine, single administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, single administration

Based on this trial design, predict the completion outcome and termination type (if applicable).